fibroblasts, to another lineage. Direct conversion of fibroblasts into neurons 6, 7 presaged serially more precise inductions of specific neuronal phenotypes, including dopaminergic neurons and motor neurons.
Neurons are generated early in neural development, and much is known about their molecular ontogeny and transcription factor codes. As a result, generating them from pluripotent cells or directly from somatic cells has required relatively short differentiation protocols involving well-studied transcription factors. In contrast, oligodendroglial differentiation is not as well understood and occurs much later in development; human neurogenesis begins within the first month after conception, whereas oligodendroglial production does not begin in earnest until four months later. Consequently, strategies for stroke and vascular dementia to the childhood leukodystrophies and cerebral palsy. All of these disorders, in some way, shape or form, involve the loss of central oligodendrocytes. Oligodendrocytes are one of the two major types of macroglial cells, the other being astrocytes; together, these cells arise from bipotential glial progenitor cells, which pervade the adult as well as the developing central nervous system.
To meet the challenge of finding renewable sources of transplantable glia and neurons, investigators have developed protocols for the neural differentiation of pluripotent stem cells, especially induced pluripotent stem cells, which can be derived from the somatic cells of patients and should be relatively nonimmunogenic 4, 5 . More recent work has focused on skipping the pluripotent stage altogether to permit the direct differentiation of one somatic phenotype, such as
The complexity of neural connectivity in the human brain may seem an insurmountable obstacle to neurological therapies based on cell transplantation. Yet studies in various animal models of disease continue to provide evidence of the functional benefits to be gained by injecting neural cells into the brain. Disorders of the white matter, in particular, may be especially tractable to cell therapy given the relative homogeneity of central oligodendrocytes, the myelin-producing cell type of the adult brain 1 . A major hurdle in this field is preparing human glial progenitor cells-also known as oligodendrocyte progenitor cells-in the numbers and purity needed for clinical transplantation, and most studies have necessarily relied upon fetal tissue as a cell source.
In this issue, two teams report the direct conversion of murine embryonic fibroblasts to glial progenitor cells capable of differentiating to myelinogenic oligodendrocytes. Tesar and colleagues 2 and Wernig and colleagues 3 carry out combinatorial screening of transcription factors important for glial identity to derive a core set of factors sufficient to instruct oligodendrocytic reprogramming (Fig. 1) . Notably, the gene sets identified by the two groups are only partially overlapping, and although the 'induced' oligodendrocyte progenitor cells generated by each protocol can restore myelin, the cells seem to differ in lineage potential. Thus, the studies may reveal fundamental differences in fate commitment that attest to the capacity of reprogramming to fine-tune the production of desired phenotypes.
The white matter of the brain is the target of many of the major neurological diseases of man, ranging from multiple sclerosis, subcortical
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Myelinating oligodendrocytes are induced from murine embryonic fibroblasts by transcription factor-mediated reprogramming. Figure 1 Murine embryonic fibroblasts are reprogrammed by transduction with one of three sets of transcription factors to generate induced oligodendrocyte progenitor cells (iOPCs) without a pluripotent intermediary. The embryonic fibroblasts are taken from reporter mice expressing eGFP under the control of the oligodendroglial gene Plp1, allowing oligodendrocytes and iOPCs to be recognized and isolated by eGFP expression. iOPCs can be serially passaged, and they generate myelinogenic oligodendrocytes after transplantation to organotypic forebrain slices and dorsal root ganglia (DRG) co-cultures in vitro, and to the hypomyelinated mouse forebrain and spinal cord in vivo. Depending upon the specific combination of transcription factors used, the iOPCs generate only oligodendrocytes or both oligodendrocytes and astrocytes. 3 use murine rather than human fibroblasts as their starting material, taking advantage of the more rapid development of murine oligodendroglia to more quickly derive protocols for their production. Tesar's group employs a combination of eight transcription factor genes, from which a core set of three genes-Sox10, Olig2 and Nkx6.2-is subsequently defined, to drive the production of induced oligodendrocyte progenitor cells. The study provides strong histological and ultrastructural evidence of efficient myelination by these cells in an elegant in vitro slice model of the congenitally hypomyelinated shiverer mouse. Remarkably, the induced progenitor cells not only are able to divide and expand for at least five passages but also appear to do so as oligodendrocyte-restricted progenitors. The authors report little evidence of astrocyte production, even though mammalian oligodendrocyte progenitor cells typically generate both astrocytes and oligodendrocytes.
Capitalizing upon an earlier assessment of differential gene expression by oligodendrocytes 9 , Wernig and colleagues 3 screen a different set of factors than that tested by Tesar and colleagues 2 . They identify Sox10, Olig2 and Zfp536 as sufficient to direct oligodendrocyte progenitor cell phenotype. Yet when fibroblasts are transduced with this combination, which includes Zfp536 in place of Nkx6.2 used in the Tesar protocol, the cells develop as bipotential glial progenitors able to give rise to both astrocytes and oligodendrocytes. This bipotential phenotype is more similar to that seen in normal mammalian development, and seems directly analogous to the bipotential oligodendrocyte progenitor cells derived by my group from both human tissue and pluripotent cells 8, 10 . However, whether the apparently distinct phenotypes observed in the two studies 2,3 merely represent differences in how the cells are assessed, or whether they indeed reflect a fundamental difference in the cells' respective lineage potentials and differentiated states, remains unclear.
If Tesar and colleagues 2 have indeed discovered a reprogramming protocol that avoids the bipotential glial progenitor stage and directly generates mitotic cells capable only of oligodendrocytic differentiation, then might these cells be developmentally downstream of the cells produced by Wernig and colleagues 3 ? Allthough most studies have found oligodendrocyte progenitor cells to be bipotential until their terminal division, more phenotypically restricted populations of glial progenitors in rodents have been reported, suggesting that the Wernig and Tesar protocols might be generating different, hierarchically defined stages of a common lineage.
The distinction in lineage competence between the glial progenitors derived in the two studies 2,3 may have implications as this approach is translated to human cells, given the differences in oligodendrocyte biology between rodents and primates. Whereas rodents seem to harbor populations of lineage-restricted oligodendroglial progenitors, we and others have noted that human oligodendroglia are every bit as post-mitotic as neurons, and their progenitors are multilineage competent 11 . Therefore, might the protocol of Tesar and colleagues 2 yield direct oligodendroglial differentiation in human cells, bypassing the bipotential stage at which astrocytes are also generated? If so, would the resulting cells lose mitotic competence with oligodendrocytic fate restriction? This might be beneficial for directing terminal differentiation but would defeat the purpose of generating stable lines of mitotic glial progenitor cells able to be expanded for clinical transplantation. In fact, this issue cuts to the core of what constitutes direct reprogramming: will the derived glial cells be able to divide as phenotypically stable clones of mitotic, myelinogenic glial progenitor cells years after their introduced reprogramming genes have ceased transcription? As such questions are assessed, it is also important to recognize that the two proto cols may not translate to human cells without modifications to the sets of transcription factors, given the differences in oligodendrocyte progenitor cell biology and fate restriction between rodents and humans.
Time and further modeling in human cells will allow these issues to be addressed and resolved, but the two groups have already made a giant leap forward in our ability to apply cellular reprogramming for direct oligodendrocytic induction and replacement. Thus, they have accomplished not just an especially challenging bit of cellular alchemy but have done so in the service of a patient population that may be especially likely to benefit from cell-based repair strategies, and especially grateful for the efforts of these pioneering investigators.
